Electroacupuncture Reduces Myocardial Ischemia-Reperfusion Injury by Inhibiting NLRP3 Inflammasome-Driven Pyroptosis in Cardiomyocytes Through Serum Exosomal miR-22-3p
By
Jian Xiong
Ying Wei
Yunnan Liu
Fayang Ling
Yi Zhao
Yu Liu
Yuxin Sun
Dehua Li
Mingsheng Sun
Dingjun Cai
Wenchuan Qi
Qianhua Zheng
Fanrong Liang
June 1, 2026
Clinical Scorecard: Electroacupuncture Reduces Myocardial Ischemia-Reperfusion Injury by Inhibiting NLRP3 Inflammasome-Driven Pyroptosis in Cardiomyocytes Through Serum Exosomal miR-22-3p
At a Glance
Category Detail
Condition Myocardial Ischemia-Reperfusion Injury (MIRI) Key Mechanisms NLRP3 inflammasome-mediated cardiomyocyte pyroptosis Target Population Patients with acute myocardial infarction (AMI) and severe ischemic heart disease Care Setting Clinical and experimental settings involving reperfusion therapy
Key Highlights
Electroacupuncture (EA) mitigates MIRI by targeting NLRP3-mediated myocardial apoptosis. Serum exosomal miR-22-3p is upregulated following EA and inhibits cardiomyocyte pyroptosis. NLRP3 inflammasome activation is a central pathological mechanism in MIRI. EA was applied at the Neiguan (PC6) acupoint in an animal model of MIRI. Guideline-Based Recommendations
Diagnosis
Assessment of myocardial infarction area and cardiac function using echocardiography. Management
Utilization of electroacupuncture as a complementary treatment for MIRI. Monitoring & Follow-up
Measurement of serum myocardial enzymes and inflammatory factors. Risks
Potential secondary damage to myocardial function due to reperfusion therapy. Patient & Prescribing Data
Patients undergoing reperfusion therapy for AMI.
Electroacupuncture may enhance recovery by modulating inflammatory responses.
Clinical Best Practices
Monitor serum exosomal miR-22-3p levels as a potential biomarker for treatment efficacy. Related Resources & Content
